Compare
Aditxt, Inc. vs Alaunos Therapeutics, Inc. vs Aspire Biopharma Holdings, Inc. vs Genelux Corp
| Latest fiscal year | Aditxt, Inc. ADTX | Alaunos Therapeutics, Inc. TCRT | Aspire Biopharma Holdings, Inc. ASBP | Genelux Corp GNLX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.2K | $5.0K | $6.2K | $8.0K |
| Revenue growth (YoY) | -97.6% | -50.0% | n/a | 0.0% |
| Gross margin | 8.4% | n/a | -1.9% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$43.10M | -$4.18M | -$24.48M | -$32.15M |
| EPS (Diluted) | -$1153.83 | -$2.20 | -$16.38 | -$0.86 |
| Operating cash flow | -$25.69M | -$2.87M | -$4.92M | -$25.27M |
| Free cash flow | -$25.70M | -$2.97M | n/a | -$26.37M |
| Cash & equivalents | n/a | $1.39M | n/a | $5.33M |
| Total assets | $16.52M | $2.97M | $1.31M | $19.03M |
| Total liabilities | $12.56M | $813.0K | $7.69M | $7.48M |
| Shareholders' equity | $5.61M | $2.15M | -$6.38M | $11.54M |
| Return on year-end equity | -768.3% | -194.0% | n/a | -278.5% |
| Shares outstanding | 411.5K | 2.35M | 3.53M | 38.14M |
Revenue, most recent five fiscal years
| Fiscal year | Aditxt, Inc. | Alaunos Therapeutics, Inc. | Aspire Biopharma Holdings, Inc. | Genelux Corp |
|---|---|---|---|---|
| Latest | $3.2K Ended 2025-12-31 | $5.0K Ended 2025-12-31 | $6.2K Ended 2025-12-31 | $8.0K Ended 2025-12-31 |
| 1 year earlier | $134.0K Ended 2024-12-31 | $10.0K Ended 2024-12-31 | n/a | $8.0K Ended 2024-12-31 |
| 2 years earlier | $645.2K Ended 2023-12-31 | $5.0K Ended 2023-12-31 | n/a | $170.0K Ended 2023-12-31 |
| 3 years earlier | $933.7K Ended 2022-12-31 | $2.92M Ended 2022-12-31 | n/a | $11.07M Ended 2022-12-31 |
| 4 years earlier | $105.0K Ended 2021-12-31 | $398.0K Ended 2021-12-31 | n/a | n/a |